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Atrial fibrillation (AF) is the most common sustained arrhythmia in the general population. As an age-related arrhythmia AF is becoming a huge
socio-economic burden for European healthcare systems. Despite significant progress in our understanding of the pathophysiology of AF,
therapeutic strategies for AF have not changed substantially and the major challenges in the management of AF are still unmet. This lack of
progress may be related to the multifactorial pathogenesis of atrial remodelling and AF that hampers the identification of causative pathophysio-
logical alterations in individual patients. Also, again new mechanisms have been identified and the relative contribution of these mechanisms still
has to be established. In November 2010, the European Union launched the large collaborative project EUTRAF (European Network of Trans-
lational Research in Atrial Fibrillation) to address these challenges. The main aims of EUTRAF are to study the main mechanisms of initiation and
perpetuation of AF, to identify the molecular alterations underlying atrial remodelling, to develop markers allowing to monitor this processes,
and suggest strategies to treat AF based on insights in newly defined disease mechanisms. This article reports on the objectives, the structure,
and initial results of this network.
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Current challenges in atrial
fibrillation management and
resulting research questions
The increase in life expectancy and recent improvements in treat-
ment of acute heart disease have resulted in a major increase
in the number of patients suffering from heart failure and atrial
fibrillation (AF). Atrial fibrillation is the most common sustained
arrhythmia in the population occurring in 1–2% of the general
population. More than 6 million Europeans suffer from this arrhyth-
mia and in an ageing society this number is expected to rise quickly.
Atrial fibrillation is associated with an increased risk of stroke, de-
mentia, heart failure, and death.1,2 In Europe, 1% or even more of
the healthcare budget is spent on AF management.3,4 Although
the socio-economic burden of AF is growing steadily and significant
progress has been made in understanding the pathophysiology of
this arrhythmia, treatment of AF patients is still far from satisfactory.
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Antiarrhythmic drugs, although reasonably effective for acute ter-
mination of AF, are unable to prevent recurrences of AF. Prevention
of thrombo-embolic events requires anticoagulation therapy with all
the associated risks. Radiofrequency ablation, originally developed
for treatment of paroxysmal AF, is not as effective in persistent
AF and is associated with potentially serious procedural risks.5
The authors believe that the relative slow progress in the devel-
opment of antiarrhythmic, ablation, and upstream AF therapies over
the past years largely reflects our inability to identify the leading mo-
lecular mechanisms of the atrial remodelling process and the occur-
rence of AF in an individual patient.6
The central objective of the large collaborative project EUTRAF
(European Network for Translational Research in Atrial Fibrillation)
is (i) to identify these main molecular mechanisms of AF progres-
sion, (ii) to develop serum, imaging, and electrophysiological
markers allowing to monitor these processes, and (iii) develop strat-
egies to treat AF based on insights in these disease mechanisms.
Mission statement of EUTRAF
The EUTRAF is a framework programme 7 large collaborative pro-
ject supported by the European Union.
EUTRAF’s general mission is to improve the management of AF in
Europe. To achieve this, methods for identification of patients who
are at-risk for AF at an early stage need to be developed and a better
understanding of the factors leading towards persistent AF need to be
obtained. Also, accurate diagnostic tools for identification of disease
mechanisms in an individual patient and new therapies for each patient
based on these individual disease mechanisms have to be defined.
More specifically EUTRAF will
† provide a multidisciplinary understanding of the diverse patho-
physiological mechanisms of AF on the molecular, cellular, tissue,
and organ level;
† integrate this knowledge into understanding of the electrophysio-
logical mechanisms initiating and perpetuating AF;
† identify and validate markers for the main molecular mechanisms
of AF that can be used in patients;
† propose a classification of AF that integrates major disease me-
chanisms and the electrophysiological characteristics of the fibril-
lating atria;
† develop new therapeutic strategies targeting individual disease
mechanisms;
† disseminate the knowledge about new diagnostic tools and thera-
peutic techniques in the public domain.
Participants and structure
of EUTRAF
EUTRAF is a multidisciplinary consortium of expert groups involved
in AF research. It was granted an amount of E12 million. The total
project budget is E16 million. The programme was launched in
November 2010. The active funding period will end by the end of
October 2015 but the research initiated and developed by EUTRAF
partners will continue for many more years.
The consortium consists of academic research groups and indus-
try partners. Expertise ranges from molecular biology, genetics, and
experimental electrophysiology, to engineering, computer science,
and cardiology. EUTRAF partners work in a matrix structure orga-
nized around central work packages (WPs) each of which will utilize
the full range of expertise provided by the network.
The consortium is led by Professor John Camm from St. George’s
University of London (UK). Table 1 gives the list of the academic and
industrial partners. These partners will define the main biological
mechanisms that lead to the slow but progressive process of atrial
remodelling increasing the propensity to AF. This atrial disease to-
gether with the molecular remodelling occurring as a consequence
of AF determine the progression of AF from paroxysmal to persist-
ent forms of the arrhythmia.
Figure 1 shows the organizational structure of EUTRAF. The basic
research undertaken to define the genetic, molecular, cellular, and
structural mechanisms of atrial remodelling are investigated in five
basic research WPs. Apart from new insights into the mechanisms
of AF, these WPs deliver new biomarkers and new therapeutic tar-
gets for AF. These suggestions are explored in two clinical WPs, one
of which focuses on new diagnostic tools for AF classification while
in others new therapeutic approaches are investigated. Data analysis
and integration is accommodated in an eighth WP, which at the
same time serves as IT platform. The consortium has access to sev-
eral datasets of large clinical trials that are used for marker validation
(e.g. Flec-SL, EAST-Trial, ANTIPAF, and the Maastricht study).7– 10
The ideas developed by EUTRAF partners have also led to the ini-
tiation of new clinical investigations as add-on studies on existing
trials, new cohorts, or new interventional trials.
Main research objectives and
recent achievements
This section describes per WP examples of research projects
undertaken by EUTRAF partners in attempt to unravel new
Table 1 Institutions participating in EUTRAF
St. George’s University of London (UK)
Maastricht University (The Netherlands)
Universite´ Pierre Marie Curie – Paris (France)
Technische Universita¨t Dresden (Germany)
Centre Hospitalier Universitaire – Bordeaux (France)
Westfa¨lische Wilhelms-Universita¨t Mu¨nster (Germany)
University Hospital Magdeburg (Germany)
Universita¨t Bern (Switzerland)
University Hospital Graz (Austria)
Medical Information Technology Solutions (Turkey)
University of Oxford (UK)
UK Health & Environment Research Institute (UK)
Sanofi-Aventis Deutschland GmbH (Germany)
Osypka AG (Germany)
Xention Ltd (UK)
Universita¨t Duisburg-Essen – Essen (Germany)
Philipps Universita¨t – Marburg (Germany)
Ernst-Moritz-Arndt Universita¨t – Greifswald (Germany)
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mechanisms of AF, to relate them to clinical signs and symptoms, to
develop new diagnostic tools for AF, and to improve current ther-
apeutics strategies.
WP1: extracellular matrix and structure–
function relationship
WP1 addresses questions related to the structural determinants of
conduction disturbances in atrial muscle. Adverse heterocellular
crosstalk between cardiac stromal and parenchymal cells at the
structural, mechanical, humoral, and electrotonic level is likely to
contribute to arrhythmogenesis in fibrotic hearts. Among the differ-
ent modalities of stroma–parenchyme interactions, it was found
that mechanical strain acting on myofibroblasts that are electrotoni-
cally coupled to myocytes causes substantial slowing of impulse con-
duction because of activation of stretch sensitive channels in
myofibroblasts resulting in a secondary depolarization of coupled
myocytes.11 With respect to humoral interactions, it was found
that the main growth factor involved in cardiac fibrotic tissue re-
modelling, transforming growth factor-b1 (TGF-b1), substantially
aggravates the arrhythmogenic effect of myofibroblasts on electro-
tonically coupled myocytes. While TGF-b1 had little effect on con-
duction in myocyte preparations, it caused significant conduction
slowing and increased ectopic activity in a fibrosis model (Figure 2).
Together, the findings suggest that arrhythmogenesis in fibrotic
hearts in the context of mechanical stress and humoral factors
may be dependent on myofibroblasts acting as primary ‘sensors’
that signal to adjacent myocytes through gap junctional coupling.
Fibroblasts and myofibroblasts can not only crosstalk to atrial
myocytes but also to adipocytes located in the epicardial adipose tis-
sue or infiltrating the myocardium. This cell type is an important
source of adipokines that can diffuse freely in the neighbouring atrial
myocardium. EUTRAF partners found that human epicardial adi-
pose tissue secretes activin A (a member of the TGF-beta family)
that has a marked fibrotic effect on the atrial myocardium by stimu-
lating myofibroblasts. EUTRAF partner currently investigate which
clinical conditions are associated with an abnormal biological activity
of epicardial adipose tissue and how this activity could contribute to
the formation of the AF substrate.12
WP2: ion-channel remodelling and
Ca21 handling
Primary objective of WP2 is the characterization of molecular indi-
cators (‘biomarkers’) and regulators of abnormal function of ion
channels in the context of AF.13 For example, EUTRAF partners
could show that shear stress increases membrane availability of
the Kv1.5-subunit underlying the ultrarapid delayed rectifier current
(IKur) from subcellular pools through an integrin-dependent path-
way, thereby shortening atrial action potential duration.14 This
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Figure 1 Organizational structure of EUTRAF. The research topics are explained in more detail in ‘Main research objectives and recent achieve-
ments’ section.
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highlights that not only the shape of the action potential15 but also
the spatial distribution of ion-channel pore units play an important
role in AF-related ion-current remodelling. There is also accumulat-
ing evidence for altered intracellular Na+-handling and downstream
Na+-dependent ion-channel regulation in AF.16 EUTRAF partners
demonstrated that both IK1 and IK,ACh are regulated by intracellular
Na+ in human atrial myocytes of SR patients, whereas Na+-
dependent regulation of IK,ACh was lost in chronic AF patients.
17
Recent EUTRAF studies have identified Ca2+-handling abnormal-
ities leading to delayed afterdepolarizations in AF patients (Ca2+
handling instability).18,19 On the other hand, sustained tachycardia
and AF as such have also been demonstrated to induce a pattern
of changes which reduce the likelihood of Ca2+-related proarrhyth-
mic cellular events (Ca2+ signalling silencing).20 It is currently
unclear whether Ca2+ instability or Ca2+ handling silencing prevails
in patients with AF.
WP3: aetiological diversity of atrial
fibrillation
Many patients with clinical AF suffer from underlying heart disease.
Hypertension, heart failure, diabetes, and ageing are all strong
predictors of AF. Accumulation of clinical factors increases the indi-
vidual risk of developing AF by adding to AF complexity, presumably
via diverse pathophysiological processes related to the underlying
conditions.
EUTRAF partners have invested considerable efforts in the devel-
opment of risk factor-based AF models to systematically identify
disease-specific mechanisms of AF. The ultimate aim is to identify
substrate-specific biomarkers related to the pathology and stage of
the underlying disease to optimize early diagnosis and therapeutic
strategies. Established animal models include rat models with genetic
hypertension or diabetes. These models are particularly suitable for
long-term studies addressing the underlying mechanisms and com-
plex interactions between ageing and disease-specific progression
of AF. For instance, atrial myocytes from hypertensive rats with early
compensated LV hypertrophy showed distinct alterations in subcellu-
lar calcium handling consisting of reduced (220%) L-type Ca2+ cur-
rent, reduced (255%) Na+/Ca2+ exchanger current and reduced
(233%) fractional SR Ca2+ release at increased SR Ca2+ load.21
Very few animal studies address the interaction between
AF-induced remodelling and disease-specific remodelling during
the development of the AF substrate. For this reason, we have es-
tablished a pig model that combines rapid pacing with hypertension.
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Figure 2 Precipitation of sustained re-entrant activity in models of fibrotic myocardium (myocyte monolayers coated with myofibroblasts).
Spontaneously arising functional re-entry (central disc, 800 mm diameter) is, in some preparations, accompanied by anatomical re-entry (periph-
eral ring of tissue, separated by a gap from the central disc). The frequency of re-entrant activity in the six preparations shown ranged from 3 to
8 Hz (voltage sensitive dye recordings).
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The combined model developed a much more severe phenotype
in terms of atrial dilatation compared with ‘lone’ AF. This was asso-
ciated with faster onset and progression of sustained AF. Eighty per
cent of hypertensive pigs had developed sustained AF (.1 h) after 2
weeks of rapid pacing, compared to (meaning: AF in 80% of pigs with
hypertension and in 20% of pigs without hypertension). This model
will prove useful for the identification of specific signalling pathways
involved in hypertension-induced structural remodelling stabilizing
and for testing the efficacy of new antiarrhythmic drugs in the setting
of hypertension.
WP4: atrial metabolic and redox
alterations in atrial fibrillation
In WP4, atrial metabolic and redox alteration are investigated as
they may provide so far unexplored targets for upstream therapy
of AF. A relevant target for such treatment strategies is the nitric
oxide-redox imbalance in the fibrillating atrial myocardium.
EUTRAF partners showed that the mechanisms responsible for
this imbalance change with the duration of AF. In the first weeks
of AF, activity and expression of NOX2 are upregulated in the left
atrial myocardium. However, in later stages (months of AF), the
oxidase systems underlying the increase in reactive oxygen species
in both atria shift from NOX2 to mitochondrial oxidases and un-
coupled nitric oxide synthases.22 Correspondingly, ex vivo incuba-
tion of atrial tissue with atorvastatin inhibits atrial Rac1 and
NOX2 activity in right atrial samples from patients who develop
AF after cardiac surgery, but does not affect atrial reactive oxygen
species production and nitric oxide synthase activity in a patients
with permanent AF.23 This implies that NOX2 inhibition by drugs
such as statins may only be effective in preventing new-onset AF
or early AF-induced electric remodelling of the atrial myocardium.
Indeed, in patients undergoing cardiac surgery, atrial superoxide and
peroxynitrite levels were independently associated with an in-
creased risk of post-operative AF and pre-operative atorvastatin
treatment for 3 days was sufficient to lower atrial NOX2 activity
and superoxide level before changes in LDL cholesterol developed.
Another related factor is the balance between atrial energy/oxy-
gen demand and supply. Little is known about how atrial oxygen
supply responds to increased demand, and under which conditions
it falls short (supply-demand mismatch). We have recently reported
that in normal healthy pigs the left atrium has a lower coronary flow
reserve than the left ventricle, but a higher oxygen extraction re-
serve.24 Although both reserves were recruited during short-term
AF, a supply-demand mismatch, as evidenced by increased lactate
production, still arose in the left atrium. This imbalance may form
a pivotal trigger that induces atrial structural changes in the longer
term, and may therefore represent another interesting target for
upstream therapy.
WP5: genetic causes of atrial fibrillation
Atrial fibrillation shows familial clustering, and common genetic var-
iants on chromosome 4q25 (and others) are associated with AF. To
further understand the mechanisms conveying AF in patients with
genetic variations, a mutation that increases the late sodium current
was studied and the effects of increased expression of CREM in a
mouse model of spontaneous AF were characterized. Also, the
functional and gene-expression effects of reducing pitx2, the gene
that is closest to the genetic variants on chromosome 4q25, were
investigated.
Patients with long-QT syndrome develop short-lasting atrial ar-
rhythmias triggered by ‘atrial afterdepolarizations’.25 Using a unique
genetic model expressing a knock-in mutation of the cardiac sodium
channel with an exclusive increase in late sodium current
(D-KPQ-SCN5A knock-in), it was demonstrated that prolongation
of the atrial action potential, early afterdepolarizations and pause-
dependent atrial arrhythmias explain this monogenic form of AF.26
The myocyte-directed expression of the splice variant
CREM-IbDC-X of transcription factor CREM in mice (CREM-TG)
led to spontaneous-onset AF associated with an increased CamKII
mediated phosphorylation of RyR2.27,28 EUTRAF partners de-
scribed an arrhythmogenic substrate preceding AF in CREM-TG
mice characterized by distension of atria with disorganized and elon-
gated cardiomyocytes.29 The atrial remodelling represents a key
event in the development of AF in this model that precedes the oc-
currence of AF and is associated with atrial ectopics and triggering of
AF episodes by programmed stimulation in young transgenic mice.
Functional changes in CREM-TG atria are related to the electro-
physiological properties of atrial myocytes and further alterations
suggesting that Ca2+-dependent mechanisms also contribute to
the development of AF.
Pitx2 expression was also studied as a marker for ‘leftness’ in the
atria. EUTRAF partners could demonstrate that pitx2, a paired
homeobox transcription factor that is implicated in left–right differ-
entiation during embryonic development, is expressed at relatively
high levels in the adult left, but not right, atrium.30 It was demon-
strated that reduced pitx2 expression shortens the atrial action po-
tential, especially at short pacing cycle lengths, and predisposes to
AF in the absence of gross structural atrial abnormalities.30 EUTRAF
partners are currently trying to identify whether these genes could
be relevant as functional mediators conveying AF and/or as biomar-
kers to identify patients with ‘polygenic AF’.31
WP6: classification of atrial fibrillation
with new diagnostic tools
WP6 of EUTRAF aims at developing non-invasive tools that may
provide information on the relative degree of electrophysiological
changes in the atria. The slow but steady process of structural re-
modelling in the atria30 – 32 could possibly monitored by advanced
analysis of surface ECGs.33,34
Within the EUTRAF consortium, a large software package allow-
ing for quantification of multiple ECG parameters reflecting the
complexity of the fibrillatory pattern during AF is developed. The
analysis of AF ECGs in more than 500 AF patients using this software
package revealed that a combination of different mathematical tech-
niques (e.g. f-wave amplitude and organization index of the power
spectrum) and multiple leads has a higher predictive value for out-
come than a single method on single leads. Importantly, the ECG
predictors had a comparable or higher predictive value than estab-
lished clinical predictors such as age, gender, LV-performance, heart
dimensions, or co-morbidities.
For example, in 132 patients undergoing step-wise catheter abla-
tion, the predictive value of ECG parameters for acute termination
EUTRAF: objectives and initial results 1461
of AF (f-wave amplitude of aVR and dominant frequency of aVF, area
under the receiver operator curve AUC ¼ 0.75) was comparable
with the performance of best clinical predictors (duration of the
current AF episode plus LA diameter, AUC ¼ 0.74). The combin-
ation of clinical with ECG predictors improved C-statistics to
AUC ¼ 0.81. For long-term outcome, ECG parameters alone pre-
dicted long-term success of catheter ablation even better than clin-
ical predictors (AUC 0.82 vs. 0.68, respectively).
Because of the close anatomical relation between the oesophagus
and the left atrial posterior wall, a transoesophageal ECG (TE-ECG)
has been suggested as a technique to characterize LA electrophysio-
logical properties. So far these studies were limited to a frequency
analysis of the oesophageal ECG.35 The EUTRAF consortium devel-
oped a technique to determine the complexity of AF in the poster-
ior wall of the left atrium by fractionation analysis of the TE-ECG.
Figure 3 demonstrates the excellent match between frequency and
complexity of the atrial activation in the atrium (LA, gold standard)
and the TE-ECG. This technique is currently being evaluated
prospectively.
In order to stimulate the process of standardization and harmoniza-
tion of the assessment of AF complexity from surface ECG EUTRAF
members hosted the first European Conference for Standardization of
Advanced ECG Analysis in Arrhythmia Diagnostics focusing on Quan-
tification of the Atrial Fibrillation Substrate Complexity, in Lugano,
Switzerland, in December 2013. At this conference, details on tech-
nical standards were discussed and common studies for correlating
ECG parameters to AF mechanisms were initiated.
WP7: improving atrial fibrillation therapy
by mechanism-based therapies
Treating AF through surgical or catheter ablation is based on the
elimination of the triggers initiating the arrhythmia and/or the sub-
strate maintaining it. In paroxysmal AF, ablation successfully targets
triggers, which are mainly located in the pulmonary veins. In persist-
ent AF results are less satisfactory, presumably because of the
influence of wider atrial substrate for AF perpetuation.36 For deter-
mining a therapeutic strategy in persistent AF (localized target vs.
global intervention), the key question is whether the activation
waves that perpetuate persistent AF individually emanate from
few, stable, and localized drivers or whether the waves are transi-
tory, widely distributed and self-perpetuating. Localized drivers
are difficult to detect in persistent AF with conventional techniques
because of limitations in technology for sequential mapping, high de-
gree of electrograms fractionation, intermittent firing, and spatial
meandering of fibrillation waves.
Recent developments have allowed bi-atrial AF mapping using ac-
tivation or phase-based analysis of body-surface potentials. For this
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Figure 3 Excellent match between atrial activations (red A) in the left atrial posterior wall (upper tracing) and the TE-ECG (mid tracing). Please
note that the atrial deflections show a low complexity (low fractionation index) in both LA-electrograms as well as in the TE-ECG on the left and a
high degree of fractionation (high number of small high frequency deflections) in the right part of the tracing. Such differences are not seen in the
surface ECG.
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reason, EUTRAF partners have studied the ability of non-invasive
mapping to identify driver domains and characterize them in persist-
ent human AF.
In 103 consecutive patients with persistent AF, accurate bi-atrial
geometry relative to an array of 252-body-surface electrodes was
obtained from non-contrast CT-scan.37 The reconstructed unipolar
AF-electrograms were signal-processed to identify the drivers (focal
or re-entrant activity) and their cumulative density-map was con-
structed (Figure 4). The driver domains were catheter ablated using
AF termination as procedural endpoint in comparison with
step-wise-ablation control group. The maps showed changing
beat-to-beat wavefronts and varying spatio-temporal behaviour
of driver activities. Re-entries were not sustained and meandered
substantially but recurred repetitively. Their locations could be
described not as discrete sites but as regions. Ablation of driver re-
gions alone terminated 75 and 15% of persistent and long-lasting AF,
respectively. The procedural times were approximately two times
shorter when compared with the traditional step-wise approach.
At 6 months after the ablation, 83% patients with AF-termination
were free from AF, similar to control population undergoing step-
wise AF ablation (84%). Thus, the non-invasive system can map
AF before the procedure and help to shorten invasive procedural
time. Further clinical evaluation is currently ongoing.
WP8: insights in atrial fibrillation
mechanisms derived from information
science and analysis of large-scale datasets
Analysis of large cohorts and databases offers the opportunity not
only to validate markers identified in a hypothesis-driven approach
but also to find new associations by hypothesis-free strategies, for
example by using data-mining techniques. The first objective of
large-scale data analysis is standardized and scalable data collection,
for which a proper IT infrastructure including data warehouse was
implemented in the EUTRAF project. An additional clustered data
warehouse was built on-site for the TRAF (TuRkish Atrial Fibrilla-
tion data base) registry in the Social Security Institution of Turkey
based on the Microsoft SQL Server Enterprise 2013 database, on
which the associated Analysis Services module was run for data ana-
lysis. The required security and privacy mechanisms for all the
above-mentioned tools have been developed and implemented to
provide confidentiality of patient-specific information and to ad-
dress ethical issues based on EU directives.
The objective of these analyses is to discover mechanistic rela-
tionships between biomarkers and the development and perpetu-
ation of AF, to assess the predictive value of existing biomarkers,
and to reveal new valuable biomarkers as well as new therapeutic
targets. Through collaborations with five different groups in the
EUTRAF consortium as well as the German Network of Excellence
for Atrial Fibrillation (AF-NET), the Flec-SL, and ANTIPAF clinical
datasets as well as datasets collected by the University of Dresden
(APDRS) and Maastricht University are analysed. Finally, with the
collaboration of MITS, St. George’s University London, and the
University of Leeds, the largest national cohort of AF patients
worldwide, the TRAF database has been built.
For example, the re-analysis of the Flec-SL cohort8 through ma-
chine learning techniques has revealed that successful pharmaco-
logical conversion prior to the beginning of the survey period had
the greatest effect in predicting whether a patient would reach
the primary endpoint (conversion to persistent AF or mortality).
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Figure 4 Vest carrying 252 electrodes placed on the patient’s chest (A) during CT scan (B) to reconstruct cardiac activation which is then
analysed with a phase mapping algorithm (C ). A rotor is seen on that map (arrow). The rotors and foci are then displayed on cumulative
maps (D) to identify the most active region and hierarchize the ablation.
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The TRAF database contains the records of 545 000 patients who
had the diagnosis of non-valvular AF within the years 2008–12.
TRAF is extracted from a claims and utilization management system
called MEDULA which processes claims for all health insurance
funds in Turkey since 2007. Analysis of the TRAF database has for
example revealed that warfarin significantly increases the rates of
hospitalization, and mortality in the low-risk groups (CHA2DS2-
VASc , 2) and decreases hospitalization and mortality in high-risk
groups (CHA2DS2-VASc ≥ 2).
All of these studies will merge and culminate with the develop-
ment of a data-mining-based model and pertaining clinical decision
support system to assess the risk of AF and its complications, which
is the final innovative and scientific objective of the WP.
Outlook
The authors believe that the scientific achievements of the EUTRAF
consortium have been and will be tremendously helpful for develop-
ing better understanding of the general pathophysiology of AF.
Hopefully, this understanding will facilitate the development of fu-
ture therapeutic strategies, such as ion-channel blockers, upstream
therapy, or ablation of AF. Some of these concepts are currently
tested in clinical trials (Table 2). While potentially proving useful in
clinical practise, these concepts evolved along the traditional flow of
explorative clinical or experimental evaluation, integration in gen-
eral understanding of pathophysiology, identification of a therapeut-
ic target and validation in clinical trials (Figure 5A).
For the future, we foresee a shift in this strategy towards emphasis
on individual disease mechanisms. We acknowledge that individual
components of pathophysiological processes leading to AF, al-
though assessable by experimental research, as yet have hardly
had an impact on the choice of the therapeutic option. Experimental
research within EUTRAF and also in many other projects has shown
that inflammation, fibrosis, reactive oxygen species activation, or
fatty infiltration can all contribute to the development and perpetu-
ation of AF. However, these considerations are usually not taken
into account in the choice for an individual therapy. The reasons
are manifold and include the presence of multiple mechanisms
and temporal variability of pathomechanisms in an individual patient.
Also the individual genetic background, with the exception of
monogenetic cardiac diseases, is usually not considered in the deci-
sion on a therapeutic strategy. To overcome, this ‘translational gap’
is one of the most important challenges in the development of a
strategy for personalized AF therapy. A potential approach to this
is shown in Figure 5B.
The authors assume that in order to identify the main mechan-
isms responsible for atrial remodelling and AF and in order to deter-
mine the relative contribution of the different disease mechanisms, a
combined histological, biochemical, and complex genetics approach
is required. In this scenario, it is essential that blood samples and at-
rial tissue is available in order to detect the molecular mechanisms
leading to AF. At the same time, detailed clinical characterization
of the patients is required so that the molecular mechanisms can
be correlated to clinical signs and symptoms.
From blood samples, common gene variants (SNPs) and a list of
predefined biomarkers would need to be determined. Histological
investigation of the tissue will show degree and distribution of fibro-
sis, amyloidosis, fatty infiltration, vascular rarefaction, inflammation,
and other mechanisms. Biochemical studies will reveal ROS pro-
duction, ion-channel alterations, and activity of prohypertrophic,
profibrotic, and proinflammatory pathways (e.g. RAS, TGF-b1).
Gene-expression profiling could be used to identify differentially ex-
pressed genes informing on statistically enriched signalling pathways.
The information from all these investigations will allow for identifi-
cation of the ‘leading molecular mechanisms’ in a specific patient.
Preferably, the mechanisms should be identified on the tissue or bio-
chemical pathway level. In a second step, a mathematical model to
detect the leading molecular mechanisms from parameters mea-
sured in blood samples, ECGs, echocardiography, and clinical profile
could be constructed. From blood samples, ECGs, echocardiog-
raphy, and clinical profile information of the same patients (the
patients from whom atrial tissue was obtained) a large number of
‘features’ would be determined in each patient. A feature can be,
for example, gender, age, LA size, comorbidity, a common gene
variant, elevation of a biomarker, upregulation of a miRNA, an
ECG parameter, or a medication. From all this information, a model
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Table 2 Ongoing clinical studies testing scientific concepts developed by EUTRAF partners
Study title/
acronym
Organizing
partner site
Number of
patients
Research objective
MULTI-AF UM 220 Predictive value of new ECG and biomarkers in patients undergoing electrical cardioversion
PROTON UM 40 Identification of rotors during AF by sinusoidal recomposition and Hilbert transform of
endocardial electrograms in patients undergoing catheter ablation for AF
MAPAC UM 150 Direct contact mapping of patients undergoing open chest surgery, correlation of
conduction disturbances with tissue, serum, and ECG markers
Late-POAF UM 100 Identification of tissue, serum, and ECG markers for incident AF in SR patients undergoing
open chest surgery
STICS Oxford 1922 Randomized, double-blind, placebo-controlled trial of the effect of perioperative
rosuvastatin on post-operative AF and myocardial damage
TRAF Ankara 545 000 TRAF registry in the Social Security Institution of Turkey.
Association between comorbidities, medication, and hospitalization with progression of
AF and stroke
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is constructed that assigns a patient to the correct leading molecular
mechanisms based on a selection of features. At the end of this step,
it is possible to read out the leading molecular mechanisms from a
(hopefully) limited list of parameters that can be determined from
blood, ECGs, echocardiography, or clinical profile of the patients.
The ultimate goal of this approach is to develop a classification of
AF which is based on clinical symptoms and signs and a hopefully
short list of biomarkers but which informs on leading pathophysio-
logical mechanism of AF in a specific patient allowing for therapy tai-
lored to these mechanisms. This shift in approach would mean to
replace clustering patients in larger groups assumed to have devel-
oped comparable disease mechanisms by detecting their individual
disease mechanisms. Instead treating them according to guidelines,
decision support systems could help to identify the optimal therapy
in an individual patient.
Such strategies are more than a daydream. They have been imple-
mented in personalized medicine strategies in various chronic dis-
eases such as Alzheimer’s disease or some forms of cancer.38,39
Increasing restrictions in healthcare budgets call for reinforcement
of personalized approaches also in cardiovascular diseases. Taking
advantage of their broad and translational expertise, EUTRAF
partners are well positioned to deliver significant contributions to
this process.
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